BiotechTube
Flow Neuroscience

Flow Neuroscience

Malmö, Sweden· Est.
flowneuroscience.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.2M

Overview

Flow Neuroscience commercializes an at-home, prescription tDCS headset and digital therapeutic app for major depressive disorder (MDD). The technology, backed by over 25 years of clinical research, delivers gentle electrical stimulation to modulate brain activity linked to mood regulation, supported by a companion app providing behavioral therapy. The company has transitioned from clinical validation to commercial rollout, with real-world data from over 14,000 users and a pivotal RCT published in Nature Medicine supporting its efficacy claims. Its business model is direct-to-consumer (DTC) with a medical device certification, positioning it in the growing digital therapeutics and neuromodulation space.

Major Depressive Disorder

Technology Platform

At-home transcranial direct current stimulation (tDCS) headset combined with a behavioral therapy mobile application for the treatment of depression.

Funding History

1
Total raised:$3.2M
Seed$3.2M

Opportunities

Large, underserved global market for depression treatment, especially for patients seeking non-pharmacological options or who are treatment-resistant.
Growing acceptance of digital therapeutics and telehealth creates a favorable environment for at-home, device-based care.
Partnerships with public health systems (like the NHS) provide a pathway to scaled adoption and reimbursement.

Risk Factors

Regulatory pathway for expansion into key markets like the US is uncertain and costly.
Achieving widespread insurance reimbursement is a major hurdle.
Faces competition from both established pharmaceuticals/therapy and a growing array of digital mental health and neuromodulation solutions.

Competitive Landscape

Competes in the digital therapeutics and neuromodulation space for depression. Direct competitors include other prescription digital therapeutics (e.g., Pear Therapeutics' reSET-O, now defunct but illustrating the model) and clinic-based neuromodulation devices (TMS). Broader competition includes all antidepressant medications, psychotherapy, and a plethora of wellness/mental health apps. Flow's differentiation is its combination of hardware-based neuromodulation with software-based behavioral therapy in a single, home-use prescription product.

More companies in Neuroscience & CNS →More companies in Sweden →